Karyopharm Therapeutics (KPTI) Gross Margin (2019 - 2026)
Karyopharm Therapeutics' Gross Margin came in at 96.75% for Q2 2026, down 0.47 percentage points from 97.23% a year earlier.
Powered by 
Analysis
Karyopharm Therapeutics (KPTI) Gross Margin (2019 - 2026) Analysis & Trends
Over the trailing twelve months to Jun 30, 2026, Karyopharm Therapeutics reported Gross Margin of 96.16%, down 0.21 percentage points year-over-year; for FY2025, it was 95.93%, up 0.06 percentage points from FY2024.
- Gross Margin carries a five-year change of -1.57 percentage points (FY2020 to FY2025).
- Going back by year, Gross Margin was 95.86% in FY2024 (-0.75 pp), 96.62% in FY2023 (-0.07 pp), 96.68% in FY2022 (-1.70 pp) and 98.38% in FY2021 (+0.88 pp).
- The five-year range for quarterly Gross Margin is 94.23% (Q1 2024) to 99.41% (Q4 2021).
- Year-over-year, Gross Margin increased in three of the last seven quarters, with an average year-over-year change of -0.09 percentage points.
- The fastest year-over-year change in Gross Margin over five years came in Q2 2022 (a gain of 2.67 percentage points), and the weakest in Q4 2022 (a drop of 4.98 percentage points).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,136.97 Bn | 1,105.55 Bn | 19.71 Bn | 85.78% |
| 2 | Johnson & Johnson | 619.72 Bn | 538.25 Bn | 17.26 Bn | 68.19% |
| 3 | AbbVie | 503.40 Bn | 476.52 Bn | 12.70 Bn | 74.74% |
| 4 | Merck | 370.15 Bn | 324.53 Bn | 12.21 Bn | 73.54% |
| 5 | Novartis Ag | 298.64 Bn | 262.63 Bn | 11.24 Bn | 78.02% |
| 6 | Astrazeneca | 261.07 Bn | 234.76 Bn | 12.86 Bn | 83.60% |
| 7 | Amgen | 237.00 Bn | 192.40 Bn | 7.24 Bn | 72.04% |
| 8 | Gilead Sciences | 191.24 Bn | 165.43 Bn | 6.22 Bn | 79.76% |
| 9 | Pfizer | 170.31 Bn | 116.96 Bn | 10.94 Bn | 72.78% |
| 10 | Karyopharm Therapeutics | 12.16 Mn | -214.27 Mn | 32.35 Mn | 96.75% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 96.75% |
| Dec 31, 2025 | 95.65% |
| Sep 30, 2025 | 95.20% |
| Jun 30, 2025 | 97.23% |
| Mar 31, 2025 | 95.67% |
| Dec 31, 2024 | 95.64% |
| Sep 30, 2024 | 96.65% |
| Jun 30, 2024 | 96.58% |
| Mar 31, 2024 | 94.23% |
| Dec 31, 2023 | 95.60% |
| Sep 30, 2023 | 97.47% |
| Jun 30, 2023 | 96.82% |
| Mar 31, 2023 | 96.51% |
| Dec 31, 2022 | 94.44% |
| Sep 30, 2022 | 97.29% |
| Jun 30, 2022 | 97.63% |
| Mar 31, 2022 | 97.01% |
| Dec 31, 2021 | 99.41% |
| Sep 30, 2021 | 98.44% |
| Jun 30, 2021 | 94.96% |
API Access
Karyopharm Therapeutics Gross Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=gross-margin&ticker=KPTI&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "gross-margin", "ticker": "KPTI", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=gross-margin&ticker=KPTI&period=max&api_key=YOUR_API_KEY");
const data = await res.json();